THERALOGICS, INC.

Basic Information

P.O.Box 12613
Research Triangle Park
Durham, NC, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 170945617
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 2


  1. Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease

    Amount: $1,396,256.00

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, affect over one million Americans and significant unmet medical needs sti ...

    STTR Phase II 2012 Department of Health and Human Services
  2. Evaluation of NBD Peptides as an Adjunct Therapy for the Treatment of Non-Hodgkin

    Amount: $420,475.00

    DESCRIPTION (provided by applicant): The NF-?B family of transcription factors plays a central role in the regulation of lymphocyte proliferation, differentiation and survival. Aberrant constitutive a ...

    STTR Phase I 2010 Department of Health and Human Services
  3. NF-kB Inhibition of Lung Ischemia Repurfusion Injury

    Amount: $255,627.00

    DESCRIPTION (provided by applicant): Ischemia-reperfusion injury (IRI) is a major problem in many clinical scenarios, including myocardial infarction and stroke. IRI is also a major problem in organ t ...

    STTR Phase I 2009 Department of Health and Human Services
  4. Inhibition of IkK to treat lethal Graft-vs.-Host Disease

    Amount: $885,556.00

    DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, th ...

    STTR Phase II 2008 Department of Health and Human Services
  5. Blockade of NF-kappaB for Prevention/Treatment of GVHD

    Amount: $244,488.00

    DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the ...

    STTR Phase I 2006 Department of Health and Human Services
  6. Validation of a Novel NF-KB Inhibitor in Murine IBD

    Amount: $216,950.00

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), affect over one million Americans. Until recently, therapies for th ...

    STTR Phase I 2006 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government